Search
Neumora Therapeutics Inc
NMRAAdd to Watchlist
1.670USD
+0.050+3.09%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
304.20MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.09%
5 Days
+1.83%
1 Month
-4.57%
6 Months
+0.60%
Year to Date
-6.70%
1 Year
+103.26%
Key Figures
1.620Open
1.725High
1.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.58%Turnover Ratio
1.620Prev. Close
1.610Low
1.18MTurnover
LossP/E Static
4.30P/B
0.00%Div Yield TTM
-108.32%ROA
3.65052wk High
0.45Volume Ratio
-243.79MNet Profit
182.16MShares
-1.3261EPS TTM
--Beta
-148.74%ROE
0.69052wk Low
7.10%Amplitude
--Gross Margin
304.20MMarket Cap
-1.03Reward/Risk
7.23%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
Neumora Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neumora Therapeutics Inc Info
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Ticker SymbolNMRA
CompanyNeumora Therapeutics Inc
CEOBerns (Paul L)
Websitehttps://neumoratx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Neumora Therapeutics Inc (NMRA)?
The current price of Neumora Therapeutics Inc (NMRA) is 1.67.
What is the symbol of Neumora Therapeutics Inc?
The ticker symbol of Neumora Therapeutics Inc is NMRA.
What is the 52-week high of Neumora Therapeutics Inc?
The 52-week high of Neumora Therapeutics Inc is 3.65.
What is the 52-week low of Neumora Therapeutics Inc?
The 52-week low of Neumora Therapeutics Inc is 0.69.
What is the market capitalization of Neumora Therapeutics Inc?
The market capitalization of Neumora Therapeutics Inc is 304.20M.
Is Neumora Therapeutics Inc (NMRA) currently rated as Buy, Hold, or Sell?
According to analysts, Neumora Therapeutics Inc (NMRA) has an overall rating of Buy, with a price target of 6.43.
What is the Earnings Per Share (EPS TTM) of Neumora Therapeutics Inc (NMRA)?
The Earnings Per Share (EPS TTM) of Neumora Therapeutics Inc (NMRA) is -1.45.